Advertisement
AKBA vs PAHC
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Hold and PAHC is a Hold.
AKBA sees MACD Histogram crosses below signal line
AKBA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 37 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AKBA as a result. In 63 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for AKBA entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in 227 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AKBA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.891) is normal, around the industry mean (43.873). P/E Ratio (0.000) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.115) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. AKBA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
PAHC in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 02, 2026
PAHC broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In 32 of the 40 cases the stock fell afterwards. This puts the odds of success at 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 62 cases where PAHC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PAHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for PAHC entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 29, 2026. You may want to consider a long position or call options on PAHC as a result. In 64 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for PAHC just turned positive on October 01, 2026. Looking at past instances where PAHC's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.
PAHC moved above its 50-day moving average on September 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PAHC crossed bullishly above the 50-day moving average on October 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +3.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAHC advanced for three days, in 212 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.761) is normal, around the industry mean (43.873). P/E Ratio (14.700) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.350) is also within normal values, averaging (2.152). Dividend Yield (0.013) settles around the average of (0.005) among similar stocks. P/S Ratio (0.953) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. PAHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 62 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
AKBA | PAHC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 92 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 45 Fair valued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 62 | |
SMR RATING 1..100 | 99 | 34 | |
PRICE GROWTH RATING 1..100 | 92 | 54 | |
P/E GROWTH RATING 1..100 | 100 | 94 | |
SEASONALITY SCORE 1..100 | 25 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PAHC's Valuation (10) in the Pharmaceuticals Major industry is somewhat better than the same rating for AKBA (45) in the Biotechnology industry. This means that PAHC’s stock grew somewhat faster than AKBA’s over the last 12 months.
PAHC's Profit vs Risk Rating (62) in the Pharmaceuticals Major industry is somewhat better than the same rating for AKBA (100) in the Biotechnology industry. This means that PAHC’s stock grew somewhat faster than AKBA’s over the last 12 months.
PAHC's SMR Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for AKBA (99) in the Biotechnology industry. This means that PAHC’s stock grew somewhat faster than AKBA’s over the last 12 months.
PAHC's Price Growth Rating (54) in the Pharmaceuticals Major industry is somewhat better than the same rating for AKBA (92) in the Biotechnology industry. This means that PAHC’s stock grew somewhat faster than AKBA’s over the last 12 months.
PAHC's P/E Growth Rating (94) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that PAHC’s stock grew similarly to AKBA’s over the last 12 months.
| AKBA | PAHC | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 85% | N/A |
| Stochastic ODDS (%) | 1 day ago 72% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 88% | 1 day ago 74% |
| MACD ODDS (%) | 1 day ago 88% | 1 day ago 76% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 71% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 75% |
| Advances ODDS (%) | 25 days ago 84% | 1 day ago 74% |
| Declines ODDS (%) | 1 day ago 86% | 4 days ago 74% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 80% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 67% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AKBA’s FA Score shows that 0 FA rating(s) are green while PAHC’s FA Score has 1 green FA rating(s).
- AKBA’s FA Score: 0 green, 5 red.
- PAHC’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AKBA’s TA Score shows that 4 TA indicator(s) are bullish while PAHC’s TA Score has 5 bullish TA indicator(s).
- AKBA’s TA Score: 4 bullish, 4 bearish.
- PAHC’s TA Score: 5 bullish, 4 bearish.
Price Growth
AKBA (@Pharmaceuticals: Generic) experienced а -14.64% price change this week, while PAHC (@Pharmaceuticals: Generic) price change was +1.55% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.28%. For the same industry, the average monthly price growth was -2.33%, and the average quarterly price growth was +12.08%.
Reported Earning Dates
AKBA is expected to report earnings on Oct 29, 2026.
PAHC is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-4.28% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
PAHC and
Correlation & Price change
A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with ZTS. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then ZTS could also see price increases.
| Ticker / NAME | Correlation To PAHC | 1D Price Change % | ||
|---|---|---|---|---|
| PAHC | 100% | +0.13% | ||
| ZTS - PAHC | 61% Loosely correlated | +4.16% | ||
| ELAN - PAHC | 47% Loosely correlated | +4.39% | ||
| VTRS - PAHC | 29% Poorly correlated | +4.47% | ||
| LFCR - PAHC | 27% Poorly correlated | +0.31% | ||
| AKBA - PAHC | 27% Poorly correlated | -0.93% | ||
More | ||||